Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
698 people get THRX articles and Market Currents by email alert.
Get email alerts on THRX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
Marketwire (May 13, 2013)
-
Marketwire (May 10, 2013)
-
Marketwire (Apr 25, 2013)
-
Marketwire (Apr 23, 2013)
-
Marketwire (Apr 22, 2013)
-
-
Marketwire (Apr 18, 2013)
-
Marketwire (Apr 17, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
Theravance: Buy This Biopharma On WeaknessChris Lau • Mon, Aug 13, 2012
-
Theravance: Vote Of Confidence?The Value Investor • Tue, Apr 3, 2012 -
-
-
Theravance May Be Moving HigherM. E. Garza • Wed, Nov 9, 2011 -
Theravance: Fairly Balanced Risk / Reward ProfileZacks Investment Research • Thu, Dec 30, 2010 -
-
Theravance Narrows Its LossesZacks Investment Research • Fri, Apr 24, 2009
-
FDA Sets Date for Theravance Drug ReviewBrett Scott • Fri, Jan 11, 2008
-
-
-
-
-
-
-
-
-
-
-
-
Seth Klarman's Top Stock PicksInsider Monkey • Wed, Feb 20
-
-
-
-
-
-
Tracking Seth Klarman's Baupost Group Holdings - Q3 2012 UpdateJohn Vincent • Wed, Nov 14, 2012
-
-
For NovaBay, Simplicity Is The Father Of InventionRyan's View • Mon, Nov 12, 2012
-
Theravance's CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 30, 2012 • 1 Comment
-
Theravance Inc. CEO Discusses Q3 2010 Results - Earnings Call TranscriptThu, Oct 21, 2010
-
Theravance Inc Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
Theravance Inc. Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Theravance, Inc. Q3 2009 Earnings Call TranscriptTue, Oct 27, 2009
-
Theravance, Inc. Q4 2008 Earnings Call TranscriptThu, Feb 12, 2009
-
Theravance, Inc. Q3 2008 Earnings Call TranscriptWed, Oct 29, 2008
-
Marketwire (May 13, 2013)
-
Marketwire (May 10, 2013)
-
Marketwire (Apr 25, 2013)
-
Marketwire (Apr 23, 2013)
-
Marketwire (Apr 22, 2013)
-
Marketwire (Apr 18, 2013)
-
Marketwire (Apr 17, 2013)
-
Marketwire (Apr 17, 2013)
-
at CNBC.com (Apr 15, 2013)
-
Marketwire (Apr 11, 2013)
-
Marketwire (Feb 21, 2013)
-
Marketwire (Feb 13, 2013)
-
Marketwire (Feb 12, 2013)
-
Marketwire (Jan 31, 2013)
-
Marketwire (Jan 29, 2013)
-
Marketwire (Jan 24, 2013)
THRX vs. ETF Alternatives
Company Description
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. We are focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Monday, May 13, 9:10 AM
Premarket gainers: UNIS +25%. SUTR +20%. THRX +13%. PERI +13%. NBG +11%. IGLD +10%. TSLA +6%. CSIQ +5%. SPWR +5%.
Losers: AFFY -8%. UNXL -5%. Comment! [On the Move] - Friday, May 10, 12:09 PM GlaxoSmithKline (GSK +1.5%) and Theravance (THRX +11%) both move higher today after the FDA approves Breo Ellipta for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema. The approval was widely expected after a federal advisory panel endorsed the product last month. Comment! [Healthcare, On the Move]
-
Friday, April 26, 9:11 AM
Premarket gainers: LOGM +19%. AVNR +16%. SYNA +17%. QLIK +12%. CRIS +9%. DHI +7%. THRX +7%. MUX +7%. JCP +7%. CSTR +6%.
Losers: PKI -14%. SIMO -11%. BIDU -9%. KEG -8%. SDT -5%. Comment! [On the Move] - Thursday, April 25, 4:48 PM Theravance (THRX) races 8% higher in late trading. Concurrently with the release of its Q1 report, THRX announces it intends to split into two independent publicly traded companies. One of the companies will remain focused on "biopharmaceutical operations,"while the other will dedicate itself to managing the "late-stage respiratory assets partnered with GlaxoSmithKline." In other words: THRX is creating a separate company to manage Breo Ellipta/Relvar, the COPD inhaled treatment recently recommended for approval in an FDA panel vote. Comment! [Healthcare, Earnings, On the Move]
-
Thursday, April 18, 9:10 AM
Premarket gainers: PTGI +33%. THRX +17%. TZOO +11%. ALSN +8%. TSM +7%. MM +6%.
Losers: EXAS -26%. NOK -11%. UNXL -10%. 1 Comment [On the Move] - Thursday, April 18, 8:17 AM Theravance (THRX) looks poised for a strong session after an FDA advisory panel recommends approval of a once-daily COPD inhaled treatment option (Breo Ellipta) the company is developing with GlaxoSmithKline (GSK). Some color on the story: 1) the drug will be called "Relvar" in the U.S. 2) Annual sales should come in at ~$337M next year. 3) Treatment may be used in conjunction with GSK's $8B per year Advair. 4) Relvar will compete with AstraZeneca's Symbicort which had sales of $3.19B in 2012. THRX shares +16% premarket. 1 Comment [Healthcare, On the Move]
- Wednesday, April 17, 7:59 PM Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an all-day trading halt while awaiting the FDA's decision on its COPD inhaler Breo Ellipta. The stock most recently traded at $33.25, after being halted earlier this morning at $28.01, as the FDA voted solidly in favor of approval. Comment! [Healthcare, On the Move]
-
Monday, April 15, 12:50 PM
Midday top 10 gainers: MKTAY +143%. CNIT +21%. GENE +21%. THRX +18%. MCOX +17%. SGRP +14%. S +13%. STXS +10%. ACOR +9%. LIFE +8%.
Midday top 10 losers: UNTK -48%. GSS -19%. ASM -18%. DSCO -17%. HXM -16%. XPL -16%. NGD -16%. TGD -15%. BAA -14%. PZG -14%. Comment! [On the Move] - Monday, April 15, 11:12 AM Theravance (THRX +20.6%) tops the leader board as a staff report suggests Breo — a COPD treatment the company is developing with GlaxoSmithKline (GSK +3.1%) — could be set for approval by the FDA which will evaluate a recommendation Wednesday. There were some questions about side effects which Citi and UBS analysts said were expected. THRX will get royalties of 15% on the first $3B in sales and 5% thereafter. 1 Comment [Healthcare, On the Move]
-
Monday, April 15, 9:15 AM
Premarket gainers: S +16%. SVA +13%. BCRX +10%. LIFE +8%. NFP +7%. MGT +7%. TMO +6%. THRX +5%. NVAX +5%.
Losers: AAU -15%. MTL -10%. AUQ -11%. HMY -9%. NGD -8%. CEF -8%. SLW -8%. SAND -9%. KGC -7%. AUY -7%. GOLD -7%. MUX -7%. DSCO -7%. IAG -6%. SVM -6%. GG -6%. PAAS -6%. EGO -6%. AU -5%. CDE -5%. Comment! [On the Move] - Monday, March 11, 2:06 PM Theravance (THRX -1.6%) slips despite the announcement that it's entered into an exclusive commercialization agreement with Clinigen Group in the European Union, as well as certain other countries located in Europe, for Vibativ, a treatment for hospital-acquired pneumonia. THRX will receive a $5M upfront payment from Clinigen and is entitled to receive tiered royalties on net sales ranging from 20% to 30%. Comment! [Healthcare, On the Move]
- Wednesday, January 9, 12:12 PM Theravance (THRX +3.2%) and GlaxoSmithKline (GSK +0.1%) have submitted a regulatory application to the E.U. for Anoro, an investigational combination medicine for patients with chronic obstructive pulmonary disease. The companies submitted a regulatory application in the U.S. for the drug last December. Comment! [Healthcare, On the Move, Global & FX]
- Tuesday, December 18, 2012, 11:31 AM Theravance (THRX +2.4%) and GlaxoSmithKline (GSK +0.6%) have submitted a New Drug Application for the investigational drug UMEC/VI (LAMA/LABA), named Anoro Ellipta, which is a potential treatment for patients with chronic obstructive pulmonary disease. The companies also intend to file regulatory applications in the European Union as well as other countries in the coming year. Comment! [Healthcare, On the Move]
- Monday, July 2, 2012, 2:38 PM Piper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin, highlighting BioMarin (BMRN +3.8%), Affymax (AFFY +1%), Theravance (THRX +8.3%), and Rigel Pharmaceuticals (RIGL +2.3%) all as potential candidates. Piper notes that BioMarin could fetch as much as $79 per share, and notes that Japanese drug heavyweight Takeda Pharmaceuticals (TKPYY.PK) could be the most likely suitor for Affymax. Comment! [Healthcare, On the Move, M&A]
- Monday, July 2, 2012, 8:18 AM GSK's (GSK) once-daily lung drug LAMA/LABA performed well in late-stage testing in patients with chronic obstructive pulmonary disease. GSK, which plans to begin filing for regulatory approval at the end of the year, hopes LAMA/LABA will be a successor to Advair. GSK is developing the drug with Theravance (THRX), whose shares are +8%. Comment! [Healthcare, On the Move]
- Monday, April 2, 2012, 7:49 AM GlaxoSmithKline (GSK) buys 10M shares of Theravance (THRX) at a price of $21.2887 a pop - taking its stake in the asthma drug firm up to 26.8%. The transaction needs the approval of Theravance's stockholders before closing. Premarket: GSK +0.7%, THRX inactive. Comment! [M&A, On the Move, Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
smokeyRose
on the Filp side I lost a little on $THRX was up now down but i will long this Money maker! - View all 0 replies
-
- View all 0 replies
-
Red Acre Investments
just published part 1 of our April Biotech binary event watch : http://bit.ly/ZmquIg $AGN, $THRX, $ENDP, $SCMP, $GILD - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Skull & Bones
Some kind of BIG news on $THRX looks imminent.......interesting price movement in the shares over the past several days. - View all 0 replies
LATEST REPLIES
-
Scott Matusow
I will be writing about $LGND and others very soon. some other good one out there like $IPXL and $THRX - View all 3 replies
-
-
-
- View all 1 replies
-
